FDA approves Dificid for C. difficile treatment in children

The FDA has approved Dificid tablets and oral suspension for the treatment of Clostridioides difficile-associated diarrhea in pediatric patients aged older than 6 months, according to a news release.The approval is based on a phase 3 study in which Dificid (fidaxomicin, Merck) showed improved efficacy compared with vancomycin in pediatric patients with C. difficile. Fidaxomicin tablets were previously approved for the treatment of C. difficile-associated diarrhea in adults aged older than 18 years,“C. difficile is an important cause of health care- and community-associated diarrhealRead More

Share on facebook
Share on twitter
Share on linkedin